User: Guest  Login
Document type:
journal article 
Author(s):
Rüschoff, J; Nagelmeier, I; Baretton, G; Dietel, M; Höfler, H; Schildhaus, HU; Büttner, R; Schlake, W; Stoss, O; Kreipe, HH 
Title:
[Her2 testing in gastric cancer. What is different in comparison to breast cancer?] 
Abstract:
Based on data from a large multicenter phase III trial (ToGA study) trastuzumab has very recently been approved by the EMEA for metastatic gastric cancer and adenocarcinoma of the gastro-esophageal junction. Only patients with tumors which over express Her2 as defined by IHC2+ and a confirmatory FISH+ result, or IHC 3+, determined by an accurate and validated assay are eligible for trastuzumab therapy. However, testing of Her2 status by immunohistochemistry (IHC) differs from breast cancer in co...    »
 
Journal title abbreviation:
Pathologe 
Year:
2010 
Journal volume:
31 
Journal issue:
Pages contribution:
208-17 
Language:
de 
Print-ISSN:
0172-8113 
TUM Institution:
Institut für Allgemeine Pathologie und pathologische Anatomie